Maximus Expands Stock Purchase Program

Maximus (NYSE:MMS) has announced the authorization of an expansion to its stock purchase program, allowing for the acquisition of up to $200 million worth of Maximus common stock. This includes the approximately $6 million remaining availability under the existing stock purchase program. Since March 31, 2024, Maximus has already purchased 538,978 shares for approximately $44.5 million.

The expansion of the stock purchase program reflects Maximus' commitment to an opportunistic approach in purchasing its common stock. Bruce Caswell, the President and CEO of Maximus, stated that the company's capital allocation priorities remain unchanged and are based on a disciplined approach that is believed to be most beneficial to shareholders.

Maximus intends to carry out the purchase of shares opportunistically at prevailing market prices in the open market, or in privately negotiated transactions. The amount and timing of purchases will be dependent on market conditions, corporate needs, and other relevant factors.

As a leading strategic partner to governments worldwide, Maximus is focused on improving the delivery of public services amid complex challenges. The company's offerings include innovative business process management, impactful consulting services, and technology solutions aimed at providing improved outcomes for the public and higher levels of productivity and efficiency of government-sponsored programs. Following these announcements, the company's shares moved 3.6%, and are now trading at a price of $87.87. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.